SCHEMBL29396880

SCHEMBL29396880

O=C(NC1(c2ccc(-c3ccc(COCc4cncnc4)cc3)cc2)CC1)OC1CN2CCC1CC2

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 4/20 0.41
▸ BCHE P06276 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ NTMT1 Q9BV86 7/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CHRM3 P20309 3/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ UGCG Q16739 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29387501 0.94 HRH3 (0.34) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL29399370 0.91 NTMT1 (0.43) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL16007035 0.89 CHRNA7 (0.46) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL16007179 0.81 CHRNA7 (0.59) CHRNA7BCHEACHECHRM3CHRM2
SCHEMBL16007049 0.80 CHRM3 (0.51) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL30745971 0.80 CHRM3 (0.51) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL16007046 0.80 CHRM3 (0.51) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL29384752 0.78 HRH3 (0.38) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL29356578 0.78 NTMT1 (0.52) CHRNA7BCHEACHENTMT1NPC1
SCHEMBL15577856 0.77 POLB (0.37) UGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC CHRNA7 4254/4885BCHE 1228/4885ACHE 3056/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885BCHE 972/4885ACHE 3555/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CHRNA7 4631/4885BCHE 972/4885ACHE 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback